Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
Pain Medicine (Malden, Mass.)|June 6, 2019
Dilemma of Addiction and Respiratory Depression in the Treatment of Pain: A Prototypical Endomorphin as a New ApproachLynn Webster, William K SchmidtAdvances in Therapy|December 9, 2023
A Randomized Controlled Trial of a Novel Formulation of Ketorolac Tromethamine for Continuous Infusion (NTM-001) in Healthy VolunteersJoseph V Pergolizzi, Amanjot Batra, William K SchmidtHospital Practice (1995)|March 13, 2012
Evaluating therapeutic benefit in postsurgical analgesia requires global assessment: an example from liposome bupivacaine in hemorrhoidectomyWilliam K Schmidt, Gary Patou, Girish P JoshiAdvances in Therapy|July 30, 2024
A Novel Formulation of Ketorolac Tromethamine (NTM-001) in Continuous Infusion in Adults with and without Renal Impairment: A Randomized Controlled Pharmacologic StudyJoseph V Pergolizzi, Amanjot Batra, William K SchmidtPharmacology & Therapeutics|June 24, 2017
Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseasesKaren M Wagner, Cindy B McReynolds, William K Schmidt, et al.International Medical Case Reports Journal|February 14, 2015
An open-label pilot study of pulsed electromagnetic field therapy in the treatment of failed back surgery syndrome painWayne L Harper, William K Schmidt, Nicole J Kubat, et al.Current Medical Research and Opinion|July 21, 2011
Onset of action of diclofenac potassium liquid-filled capsules in dental surgery patientsJohn R Zuniga, Robert J Noveck, William K Schmidt, et al.Journal of Opioid Management|March 28, 2017
In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodoneD Lynn Kirkpatrick, William K Schmidt, Ricardo Morales, et al.Clinical and Translational Science|March 21, 2024
Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi-ascending dose study with a bioequivalence arm in healthy volunteersD Lynn Kirkpatrick, Cari Evans, Linda A Pestano, et al.Journal of Opioid Management|March 3, 2026
Formulation development and a Phase 1 clinical study of PF614-MPAR, an oxycodone prodrug with oral opioid overdose protectionD Lynn Kirkpatrick, Linda A Pestano, Cari Evans, et al.Pageof 2